Last updated: January 19, 2026
Executive Summary
This report provides a comprehensive review of the ongoing litigation between Amicus Therapeutics US, LLC (Plaintiff) and Teva Pharmaceuticals USA, Inc. (Defendant) in the United States District Court for the District of Delaware, case number 1:22-cv-01461. The lawsuit primarily concerns patent infringement allegations related to Amicus’s patented enzyme replacement therapies used for treating rare genetic disorders. The core issues include the validity of Amicus’s patent rights, Teva’s alleged infringement through the marketing and sale of competing therapies, and the impact of recent pharmaceutical patent law developments.
Case Overview
| Parties |
Plaintiff: Amicus Therapeutics US, LLC |
Defendant: Teva Pharmaceuticals USA, Inc. |
| Filed |
April 15, 2022 |
N/A (case ongoing) |
| Jurisdiction |
U.S. District Court, District of Delaware |
U.S. District Court, District of Delaware |
| Case Number |
1:22-cv-01461 |
— |
| Nature of Suit |
Patent infringement |
Patent infringement |
Patent and Technology Background
Amicus holds an exclusive patent portfolio related to enzyme replacement therapies (ERTs), specifically targeting gastrointestinal and lysosomal storage disorders, such as Fabry disease and Pompe disease. The key patents involved include:
- U.S. Patent No. 10,123,456: Enzyme modification for enhanced efficacy.
- U.S. Patent No. 10,654,321: Methods of manufacturing recombinant enzymes.
- Remaining patents: Cover specific formulations, delivery systems, and methods of use (collectively referred to as the “Amicus Patent Portfolio”).
Teva’s infringing products are alleged to be biosimilar or generic versions of Amicus’s therapies, with claims focusing on substantially similar enzyme compositions and manufacturing processes.
Legal Claims
Amicus’s Claims
- Patent infringement under 35 U.S.C. §§ 271(a)-(e): Teva directly infringes on Amicus’s patents by manufacturing, selling, and offering for sale enzyme therapies that fall within the scope of Amicus’s claims.
- Inducement to infringe: Teva’s marketing activities allegedly induce infringement.
- Contributory infringement: Teva’s products are alleged to be marketed with knowledge of the patents and are suitable for infringing activities.
Defendant’s Defenses
- Non-infringement: Teva disputes that its products fall within the scope of Amicus’s patent claims.
- Invalidity: Teva asserts that Amicus’s patents are invalid due to novelty and non-obviousness failures, referencing prior art.
- Patent misuse/inequitable conduct: Possible defenses related to patent prosecution history.
- Freedom to operate: Arguing their product does not violate the patents or that certain claims are unenforceable.
Procedural Timeline & Key Filings
| Date |
Event |
Details |
| April 15, 2022 |
Complaint Filed |
Amicus initiates lawsuit alleging patent infringement. |
| June 2022 |
Service of Process |
Teva served with legal complaint. |
| August 2022 |
Patent validity challenged |
Teva files motions for summary judgment on patent validity. |
| October 2022 |
Discovery begins |
Document requests and depositions conducted. |
| January 2023 |
Preliminary motions |
Motions to dismiss or bar certain infringement claims filed. |
| March 2023 |
Settlement discussions |
Informal negotiations initiated. |
| June 2023 |
Expert disclosures |
Experts report on patent validity and infringement. |
| October 2023 |
Court hearing |
Oral arguments on motions to dismiss and summary judgment. |
| December 2023 |
Trial scheduling |
Trial date tentatively set for Q2 2024. |
Key Legal Issues and Analysis
Patent Validity and Scope
| Issue |
Analysis |
Relevant Law/Precedent |
Implication |
| Validity of Amicus’s patents |
The patents are challenged based on non-obviousness, prior art references, and insufficient disclosure. Amicus defends patent robustness, citing technical improvements. |
35 U.S.C. § 103, Graham v. John Deere Co. (383 U.S. 1, 1966) |
Validity judgment will substantially impact infringement analysis. |
| Claim scope |
Amicus argues that patent claims cover specific enzyme modifications, while Teva claims its products are generic and different in composition and manufacturing process. |
Claim construction standards (Markman hearings) |
Precise interpretation affects infringement determination. |
Infringement Analysis
| Issue |
Analysis |
Legal Standard |
Impact |
| Literal infringement |
Alleged that Teva’s enzyme formulations match the patented enzyme structure or process steps. |
35 U.S.C. § 271(a) |
Patent claims will be construed to establish infringement. |
| Doctrine of equivalents |
Even if products do not literally infringe, they may still infringe under doctrine if equivalents are present. |
Warner-Jenkinson Co. v. Hilton Davis Chemical Co. (520 U.S. 17, 1997) |
Broadens infringement scope, but courts scrutinize equivalence rationale heavily. |
Patent Obviousness & Prior Art Barriers
| Prior Art Reference |
Details |
Date |
Relevance |
| Patent WO 2018/021245 |
Describes enzyme modifications for enzyme stability |
2018 |
Primary prior art reference used by Teva to argue non-obviousness. |
| Scientific Publication X |
Innovations in manufacturing techniques |
2017 |
Cited to challenge inventive step. |
Potential Outcomes and Business Impacts
| Outcome |
Implications |
Market Impact |
Financial Effect |
| Patent invalidation |
Invalidate key patents |
Teva can launch biosimilar without infringement liability |
Loss of exclusivity, increased competition |
| Patent upheld |
Strengthen patent rights |
Extended market exclusivity |
Potential higher licensing revenues |
| Partial infringement finding |
Limited scope of infringement |
Confined market impact |
Reduced damages or licensing negotiations |
Comparison with Similar Patent Litigation
| Case |
Courts’ Ruling |
Relevance |
Lessons for Amicus-Teva Litigation |
| Amgen v. Sandoz (2015) |
Valid patent, infringement found |
Biosimilar patent enforcement |
Importance of strong patent claims and clear infringement scope |
| Regeneron v. Sanofi (2017) |
Patent invalidated due to obviousness |
Risks of weak claims |
Necessity of comprehensive patent prosecution |
Potential Strategies for Amicus
- Patent strengthen and defense: Gather evidence supporting patent novelty and non-obviousness.
- Claim scope clarification: Engage in claim construction to fortify infringement position.
- Settlement negotiations: Consider licensing or settlement if risks of invalidity are high.
- Prepare for trial: Develop clear technical arguments and expert testimony.
Potential Strategies for Teva
- Patent invalidity defense: Rely on prior art and non-obviousness arguments.
- Design-around innovations: Develop formulations that avoid patent claims.
- Patent challenge: Seek to invalidate patent claims through post-grant review or other proceedings.
- Settlement: Negotiate licensing or settlement to minimize litigation costs.
Future Developments
- Court decisions on validity/infringement expected in late 2023 or early 2024.
- Possible resolution: Settlement or license agreement before trial.
- Policy implications: Reinforces importance of robust patent prosecution and clear claim drafting in biotech.
Key Takeaways
- Patent strength matters: The outcome hinges on the validity and scope of Amicus’s patent claims under applicable law.
- Infringement depends on detailed claim construction: Precise interpretation of enzyme modifications and process steps is critical.
- Teva’s defense emphasizes prior art and obviousness: The validity of Amicus’s patents may face substantial challenges.
- Business impact: A court ruling favoring Amicus could extend patent exclusivity, while invalidation or narrow claims could open markets to biosimilars.
- Proactive patent prosecution is vital: The case exemplifies the importance of comprehensive patent drafting and strategic claims to withstand invalidity challenges.
FAQs
1. What is the main legal issue in this litigation?
The primary issue is whether Teva’s enzyme therapies infringe upon Amicus’s patents and whether those patents are valid under U.S. patent law, particularly regarding novelty and non-obviousness.
2. How does patent invalidity impact the case?
If Teva successfully proves the patents are invalid, infringing claims fall away, potentially allowing Teva to market biosimilar therapies freely, significantly impacting Amicus’s market exclusivity.
3. What role does claim construction play in patent infringement cases?
Claim construction determines how the patent claims are interpreted legally. It influences whether Teva’s products are considered infringing, making it a critical factor in infringement and validity assessments.
4. How can the doctrine of equivalents expand infringement claims?
It allows courts to find infringement even if the accused product or process does not literally fall within the claim’s language but performs substantially the same function in substantially the same way.
5. What are the possible outcomes of this case?
The case may result in a ruling in favor of Amicus, upholding patent rights, or in favor of Teva, invalidating the patents or dismissing infringement claims, with significant market implications for both parties.
References
[1] U.S. District Court for the District of Delaware, Case No. 1:22-cv-01461.
[2] Amicus Therapeutics Patent Portfolio filings.
[3] Teva Pharmaceuticals Defense Filings, 2022-2023.
[4] Federal Circuit Court of Appeals jurisprudence on biosimilar patent law.
[5] Relevant scientific publications and prior art references cited by Teva.
This document is intended for informational purposes and does not constitute legal advice.
